AQST (Aquestive Therapeutics) Institutional Ownership: 57.37% (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AQST Aquestive Therapeutics Inc AQST
49 GF Score
Price $5.16
GF Value $2.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Aquestive Therapeutics Institutional Ownership?

Aquestive Therapeutics AQST -1.15% 49 Institutional Ownership is 57.37% as of Sep. 09, 2026. GuruFocus rates AQST with a GF Score™ of 49/100 and a GF Value™ of $2.37 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aquestive Therapeutics's institutional ownership is 57.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aquestive Therapeutics's Insider Ownership is 4.17%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aquestive Therapeutics's Float Percentage Of Total Shares Outstanding is 95.53%.

Aquestive Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Aquestive Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquestive Therapeutics Institutional Ownership Chart

Aquestive Therapeutics Historical Data

The historical data trend for Aquestive Therapeutics can be seen below:

2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Institutional Ownership 19.15 22.53 22.45 23.09 22.94 22.31 23.21 25.06 25.84 26.02
AQST
49GF Score
Aquestive Therapeutics Inc AQST
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aquestive Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 57.37% mean?
Aquestive Therapeutics (AQST) has a Institutional Ownership of 57.37% as of Sep. 09, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Aquestive Therapeutics and its competitors.
Is Aquestive Therapeutics' Institutional Ownership too high?
Aquestive Therapeutics' current Institutional Ownership is 57.37%. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' Institutional Ownership compare to TLRY and EOLS?
Aquestive Therapeutics' Institutional Ownership of 57.37% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Aquestive Therapeutics and its competitors. Aquestive Therapeutics's current Institutional Ownership is 57.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current Institutional Ownership is 57.37%. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current Institutional Ownership is 57.37% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aquestive Therapeutics (AQST) Overvalued in 2026?

Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued. The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37. GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.

Key valuation signals for AQST:

  • Institutional Ownership: 57.37%
  • GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aquestive Therapeutics Business Description

Address 30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score

Get the complete analysis for AQST

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.16
Price
$2.37
GF Value